Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Devaki Patel
FDA Resolves Semaglutide Shortage: Next Steps for Community Pharmacies, Telehealth Companies, and Other Providers | JD Supra
Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties from compounding the drug. Our FDA/Food, Drug & Device and Health Care Groups have developed an initial checklist for providers to consider during the FDA’s enforcement discretion period.
FDA's New Dietary Supplement Ingredient Directory
On March 6, 2023, the U.S. Food & Drug Administration (FDA) launched a Dietary Supplement Ingredient Directory (Directory) to consolidate information about ingredients used in dietary supplements and provide information regarding the FDA's actions for any given ingredient. Specifically, the Directory includes links to the FDA's actions and statements about particular dietary ingredients and other ingredients used in products marketed as dietary supplements.
FDA’s New Dietary Supplement Ingredient Directory
On March 6, 2023, the U.S. Food & Drug Administration (FDA) launched a Dietary Supplement Ingredient Directory (Directory) to consolidate information about ingredients used in dietary supplements and provide information regarding the FDA’s actions for any given ingredient. Specifically, the Directory includes links to the FDA’s actions and statements about particular dietary ingredients and other ingredients used in products marketed as dietary supplements.
FDA’s New Dietary Supplement Ingredient Directory
On March 6, 2023, the U.S. Food & Drug Administration (FDA) launched a Dietary Supplement Ingredient Directory (Directory) to consolidate information about ingredients used in dietary supplements and provide information regarding the FDA’s actions for any given ingredient. Specifically, the Directory includes links to the FDA’s actions and statements about particular dietary ingredients and other ingredients used in products marketed as dietary supplements.
COVID-19 Related Medical Devices: FDA Finalizes Transition Plan Guidance | JD Supra
On March 27, 2023, the U.S. Food & Drug Administration (FDA) released two final guidance documents to assist with transitioning medical devices: (i) that were subject to certain enforcement policies issued during the COVID-19 Public Health Emergency (PHE), and (ii) that were issued emergency use authorizations (EUAs). These guidance documents finalize the corresponding draft guidance documents that were issued on December 23, 2021.
COVID-19 Related Medical Devices: FDA Finalizes Transition Plan Guidance
On March 27, 2023, the U.S. Food & Drug Administration (FDA) released two final guidance documents to assist with transitioning medical devices: (i) that were subject to certain enforcement policies issued during the COVID-19 Public Health Emergency (PHE), and (ii) that were issued emergency use authorizations (EUAs). These guidance documents finalize the corresponding draft guidance documents that were issued on December 23, 2021.
Foley & Lardner Comment Letter on DEA Telemedicine Controlled Substance Proposed Rule
On March 1, 2023, the Drug Enforcement Agency (DEA) officially published proposed rules for prescribing controlled substances via telemedicine after the COVID-19 Public Health Emergency expires. The DEA gave the public a 30 day window to submit comments, after which it will issue final regulations.
Modernization of Cosmetics Regulation Act of 2022: What You Need to Know
Wednesday, January 25, 2023 On December 29, 2022, President Biden signed into law the Consolidated Appropriations Act, 2023, which includes the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). MoCRA significantly changes the current regulatory framework for cosmetics in place since the enactment of the Federal Food, Drug, and Cosmetic Act (FD&C Act) in 1938.
Psychedelic Drugs – Easing the Regulatory Hurdles for Development | JD Supra
Congress recently introduced a bill that could expand access to therapeutic psychedelics that are designated as Breakthrough Therapies. These products are potentially useful in treating addiction, depression, post-traumatic stress disorder (PTSD), and other neurologic diseases.
Psychedelic Drugs - Easing the Regulatory Hurdles for Development
Congress recently introduced a bill that could expand access to therapeutic psychedelics that are designated as Breakthrough Therapies. These products are potentially useful in treating addiction, depression, post-traumatic stress disorder (PTSD), and other neurologic diseases.
Devaki Patel Healthcare Attorney Foley and Lardner
Legal Disclaimer You are responsible for reading, understanding and agreeing to the National Law Review's (NLR’s) and the National Law Forum LLC's Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only.
Hearing Aids: More Accessible to Consumers After FDA Issues Final Rule | JD Supra
Many people experience hearing loss and related hearing issues. To date, to get a hearing aid, people needed a prescription and to see a licensed hearing aid specialist in order to be properly diagnosed and fitted for a hearing aid. Now, as outlined below, the U.S. Food and Drug Administration (FDA or Agency) has issued a final rule that changes the requirements so that no prescription is necessary for people with perceived mild to moderate hearing loss.
Hearing Aids: More Accessible to Consumers After FDA Issues Final Rule
Many people experience hearing loss and related hearing issues. To date, to get a hearing aid, people needed a prescription and to see a licensed hearing aid specialist in order to be properly diagnosed and fitted for a hearing aid. Now, as outlined below, the U.S. Food and Drug Administration (FDA or Agency) has issued a final rule that changes the requirements so that no prescription is necessary for people with perceived mild to moderate hearing loss.
On the Attack: FDA Pursues Online Retail Fulfillment House | JD Supra
In an unprecedented move, the U.S. Food and Drug Administration (FDA or Agency) sent a warning letter to Amazon.com, Inc. (Amazon), a fulfillment house, with respect to distributing over-the-counter (OTC) drug products that are in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). We have seen FDA take enforcement actions against companies who introduce violative products into interstate commerce.
Hearing Aids: More Accessible to Consumers After FDA Issues Final Rule
Wednesday, August 17, 2022 Many people experience hearing loss and related hearing issues. To date, to get a hearing aid, people needed a prescription and to see a licensed hearing aid specialist in order to be properly diagnosed and fitted for a hearing aid. Now, as outlined below, the U.S. Food and Drug Administration (FDA or Agency) has issued a final rule that changes the requirements so that no prescription is necessary for people with perceived mild to moderate hearing loss.
FDA Sends Warning Letter To Amazon Online Fulfillment House
In an unprecedented move, the U.S. Food and Drug Administration (FDA or Agency) sent a warning letter to Amazon.com, Inc. (Amazon), a fulfillment house, with respect to distributing over-the-counter (OTC) drug products that are in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). We have seen FDA take enforcement actions against companies who introduce violative products into interstate commerce.
Unpacking Averages: Violations Found in Medical Device Warning Letters
Most companies want to avoid FDA warning letters. To help medical device companies identify violations that might lead to a warning letter, this post will dive deeply into which specific types of violations are often found in warning letters that the FDA issues. Background As you probably know, FDA has a formal process for evaluating inspection records and other materials to determine whether issuing a warning letter is appropriate.
HHS Withdraws Trump Administration SUNSET Rule
On May 27, 2022, the U.S. Department of Health and Human Services (HHS) issued a final rule withdrawing the Securing Updated and Necessary Statutory Evaluations Timely (SUNSET) rule, which had been promulgated in the waning days of the Trump administration and would have required most rules administered by HHS to be reviewed within 5 years of the effective date of the SUNSET rule, and then every 10 years thereafter, or else be automatically repealed.
Will FDA's Proposed Ban On Flavored Tobacco Products Ever Be Implemented?
On April 28, 2022, the U.S. Food and Drug Administration (FDA) released two proposed rules that would ban menthol as a characterizing flavor in cigarettes and prohibit all characterizing flavors such as strawberry and menthol in cigars. The proposed rules were in response to efforts to reduce youth initiation and help current smokers quit, and are part of the FDA's efforts to reduce tobacco-related health disparities.
Healthcare Regulatory Check-Up April 2022: Notable Enforcement Resolutions and Activity
PHARMA MANUFACTURER AGREES TO PAY $260M TO SETTLE LAWSUITS ALLEGING MEDICAID DRUG REBATE UNDERPAYMENTS, ILLEGAL KICKBACKS On March 9, 2022, a pharmaceutical company agreed to pay $260 million to resolve allegations that it violated the False Claims Act (FCA) by knowingly underpaying Medicaid rebates due for its drug and paying illegal subsidies in violation of the federal anti-kickback statute (AKS).
FDA Issues Warning Letters to Four Companies Selling Unapproved CBD Products for Food-Producing Animals
Legal Disclaimer You are responsible for reading, understanding and agreeing to the National Law Review's (NLR’s) and the National Law Forum LLC's Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only.
Will FDA’s Proposed Ban on Flavored Tobacco Products Ever be Implemented? | JD Supra
On April 28, 2022, the U.S. Food and Drug Administration (FDA) released two proposed rules that would ban menthol as a characterizing flavor in cigarettes and prohibit all characterizing flavors such as strawberry and menthol in cigars. The proposed rules were in response to efforts to reduce youth initiation and help current smokers quit, and are part of the FDA’s efforts to reduce tobacco-related health disparities.
FDA Issues Latest Draft Guidance On The Use Of Real-World Data And Evidence To Support Regulatory Decision-Making For Drug And Biological Products
United States: FDA Issues Latest Draft Guidance On The Use Of Real-World Data And Evidence To Support Regulatory Decision-Making For Drug And Biological Products 03 January 2022 by Devaki Patel and Kyle Y. Faget Foley & Lardner Your LinkedIn Connections with the authors To print this article, all you need is to be registered or login on Mondaq.com.
Vaping Will Not Make You Well
United States: Vaping Will Not Make You Well 30 December 2021 by Devaki Patel and Daniel Rose Foley & Lardner Your LinkedIn Connections with the authors To print this article, all you need is to be registered or login on Mondaq.com. On December 1, 2021, the U.S Food and Drug Administration (FDA) issued warning letters to several companies for marketing vaping products with unproven health claims.
FDA Issues Latest Draft Guidance on the Use of Real-World Data and Evidence to Support Regulatory Decision-Making for Drug and Biological Products | JD Supra
On December 8, 2021 and in response to the mandate under the 21st Century Cures Act to issue guidance on the use of real-world evidence (RWE) in regulatory decision-making, the U.S. Food and Drug Administration (FDA) released a draft guidance document: Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products(Draft Guidance).
FDA Issues Latest Draft Guidance on the Use of Real-World Data and Evidence to Support Regulatory Decision-Making for Drug and Biological Products
On December 8, 2021 and in response to the mandate under the 21st Century Cures Act to issue guidance on the use of real-world evidence (RWE) in regulatory decision-making, the U.S. Food and Drug Administration (FDA) released a draft guidance document: Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products(Draft Guidance).
FDA Issues Latest Draft Guidance on the Use of Real-World Data
Legal Disclaimer You are responsible for reading, understanding and agreeing to the National Law Review's (NLR’s) and the National Law Forum LLC's Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only.
Vaping Will Not Make You Well | JD Supra
On December 1, 2021, the U.S Food and Drug Administration (FDA) issued warning letters to several companies for marketing vaping products with unproven health claims. In a consumer update, FDA warned consumers that certain “wellness” vaping products containing vitamins or essential oils are being sold illegally with unproven claims. Currently, FDA has not approved any vaping products to prevent or treat any health conditions or diseases.
Vaping Will Not Make You Well
On December 1, 2021, the U.S Food and Drug Administration (FDA) issued warning letters to several companies for marketing vaping products with unproven health claims. In a consumer update, FDA warned consumers that certain “wellness” vaping products containing vitamins or essential oils are being sold illegally with unproven claims. Currently, FDA has not approved any vaping products to prevent or treat any health conditions or diseases.
FDA Cracks Down on Vaping Misinformation
Legal Disclaimer You are responsible for reading, understanding and agreeing to the National Law Review's (NLR’s) and the National Law Forum LLC's Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only.
The Proposed Cures 2.0 Act – What You Can Expect - Food, Drugs, Healthcare, Life Sciences - United States
United States: The Proposed Cures 2.0 Act – What You Can Expect 09 December 2021 by Devaki Patel , David Rosen , Jennifer Walsh and Jared Rifis Foley & Lardner Your LinkedIn Connections with the authors To print this article, all you need is to be registered or login on Mondaq.com. On November 16, 2021, U.S. House Representatives Diana DeGette (D-CO) and Fred Upton (R-MI) introduced the highly anticipated Cures 2.0 Act (H.R. 6000).
The Proposed Cures 2.0 Act – What You Can Expect | JD Supra
On November 16, 2021, U.S. House Representatives Diana DeGette (D-CO) and Fred Upton (R-MI) introduced the highly anticipated Cures 2.0 Act (H.R. 6000). Among other things, this 173-page bipartisan bill contain provisions to accelerate medical research, increase patient access to novel therapeutics, and remove current barriers to telehealth services. This bill would also create a new agency called Advanced Research Projects Agency for Health (ARPA-H) within the National Institutes of Health (NIH).
The Proposed Cures 2.0 Act - What You Can Expect
On November 16, 2021, U.S. House Representatives Diana DeGette (D-CO) and Fred Upton (R-MI) introduced the highly anticipated Cures 2.0 Act (H.R. 6000). Among other things, this 173-page bipartisan bill contain provisions to accelerate medical research, increase patient access to novel therapeutics, and remove current barriers to telehealth services. This bill would also create a new agency called Advanced Research Projects Agency for Health (ARPA-H) within the National Institutes of Health (NIH).
The Proposed Cures 2.0 Act – What You Can Expect
Monday, December 6, 2021 On November 16, 2021, U.S. House Representatives Diana DeGette (D-CO) and Fred Upton (R-MI) introduced the highly anticipated Cures 2.0 Act (H.R. 6000). Among other things, this 173-page bipartisan bill contain provisions to accelerate medical research, increase patient access to novel therapeutics, and remove current barriers to telehealth services.
CMS Changes Course By Repealing The Medicare Coverage Of Innovative Technology And Definition Of Reasonable And Necessary Rule Due To Insufficient Beneficiary Protections - Food, Drugs, Healthcare, Life Sciences - United States
United States: CMS Changes Course By Repealing The Medicare Coverage Of Innovative Technology And Definition Of Reasonable And Necessary Rule Due To Insufficient Beneficiary Protections 01 December 2021 by Devaki Patel , Jessica Boubker and Kyle Y. Faget Foley & Lardner Your LinkedIn Connections with the authors To print this article, all you need is to be registered or login on Mondaq.com.
CMS Changes Course by Repealing the Medicare Coverage of Innovative Technology and Definition of Reasonable and Necessary Rule Due to Insufficient Beneficiary Protections | Foley & Lardner LLP - JDSupra
On November 12, 2021, the Centers for Medicare and Medicaid Services (CMS) announced that it is rescinding the Medicare Coverage of Innovative Technology and Definition of “Reasonable and Necessary” (MCIT/R&N) final rule, which would have become effective on December 15, 2021.
CMS Changes Course by Repealing the Medicare Coverage of Innovative Technology and Definition of Reasonable and Necessary Rule Due to Insufficient Beneficiary Protections
On November 12, 2021, the Centers for Medicare and Medicaid Services (CMS) announced that it is rescinding the Medicare Coverage of Innovative Technology and Definition of “Reasonable and Necessary” (MCIT/R&N) final rule, which would have become effective on December 15, 2021.
FDA Calls For Repeating Clinical And Bioanalytical Studies
United States: FDA Calls For Repeating Clinical And Bioanalytical Studies 27 October 2021 by Devaki Patel and Kyle Y. Faget Foley & Lardner Your LinkedIn Connections with the authors To print this article, all you need is to be registered or login on Mondaq.com.
FDA Calls for Repeating Clinical and Bioanalytical Studies | JD Supra
Recently, the U.S. Food and Drug Administration (FDA) notified several pharmaceutical companies that they must repeat their clinical and bioanalytical studies conducted by Synchron Research Services (Synchron) or Panexcell Clinical Lab (Panexcell) due to significant data integrity concerns.
FDA Calls for Repeating Clinical and Bioanalytical Studies
Legal Disclaimer You are responsible for reading, understanding and agreeing to the National Law Review's (NLR’s) and the National Law Forum LLC's Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only.
Clinical Trials: Does FDA's Notice To Acceleron Signal A New Era Of Enforcement For Results Reporting?
United States: Clinical Trials: Does FDA's Notice To Acceleron Signal A New Era Of Enforcement For Results Reporting? 10 May 2021 by Devaki Patel and Kyle Y. Faget Foley & Lardner Your LinkedIn Connections with the authors To print this article, all you need is to be registered or login on Mondaq.com.
Clinical Trials: Does FDA’s Notice to Acceleron Signal a New Era of Enforcement for Results Reporting? | JD Supra
On April 27, 2021, the U.S. Food and Drug Administration (FDA) sent a notice of noncompliance to Acceleron Pharma (Acceleron), accusing the company of failing to post clinical trial summary results on its cancer combination drug therapy, dalantercept and axitinib, on ClinicalTrials.gov, as required by federal law.
A recurrent central giant cell granuloma in a young patient and orthodontic treatment: a case report
Central giant cell granuloma (CGCG) is an uncommon benign intraosseous lesion of the jaw, found predominantly in children and young adults below 30 years of age. The purpose of this article was to present a summary of the current literature and a case report of an 11-year-old boy diagnosed with an aggressive CGCG involving the anterior maxilla that was removed in 2004 and subsequently recurred almost 3 years later in 2006.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Devaki
Contact Devaki, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack